| Date Filed | Type | Description |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte... |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/28/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"VYNE Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule BRIDGEWATER, N.J., February 28, 2023 -- VYNE Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on February 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550 of the Nasdaq Listing Rules. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from February 13, 2023 through February 27, 2023, the closing bid p..." |
|
| 02/10/2023 |
8-K
| Quarterly results |
| 01/17/2023 |
8-K
| Quarterly results |
| 01/12/2023 |
8-K
| Results of Operations and Financial Condition, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure,... |
| 11/25/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/18/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 11/14/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/10/2022 |
8-K
| Quarterly results |
| 08/30/2022 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events ... |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/12/2022 |
8-K
| Quarterly results |
| 08/10/2022 |
8-K
| Quarterly results |
| 07/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/27/2022 |
8-K
| Quarterly results |
| 07/19/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/07/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/17/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 06/17/2022 |
8-K
| Quarterly results |
| 06/07/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/07/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/30/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/17/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|